Olupot-Olupot, Peter; Engoru, Charles; Thompson, Jennifer; Nteziyaremye, Julius; Chebet, Martin; Ssenyondo, Tonny; Dambisya, Cornelius M; Okuuny, Vicent; Wokulira, Ronald; Amorut, Denis; +8 more... Ongodia, Paul; Mpoya, Ayub; Williams, Thomas N; Uyoga, Sophie; Macharia, Alex; Gibb, Diana M; Walker, A Sarah; Maitland, Kathryn; (2014) Phase II trial of standard versus increased transfusion volume in Ugandan children with acute severe anemia. BMC medicine, 12 (1). 67-. ISSN 1741-7015 DOI: https://doi.org/10.1186/1741-7015-12-67
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
BACKGROUND: Severe anemia (SA, hemoglobin <6 g/dl) is a leading cause of pediatric hospital admission in Africa, with significant in-hospital mortality. The underlying etiology is often infectious, but specific pathogens are rarely identified. Guidelines developed to encourage rational blood use recommend a standard volume of whole blood (20 ml/kg) for transfusion, but this is commonly associated with a frequent need for repeat transfusion and poor outcome. Evidence is lacking on what hemoglobin threshold criteria for intervention and volume are associated with the optimal survival outcomes. METHODS: We evaluated the safety and efficacy of a higher volume of whole blood (30 ml/kg; Tx30: n = 78) against the standard volume (20 ml/kg; Tx20: n = 82) in Ugandan children (median age 36 months (interquartile range (IQR) 13 to 53)) for 24-hour anemia correction (hemoglobin >6 g/dl: primary outcome) and 28-day survival. RESULTS: Median admission hemoglobin was 4.2 g/dl (IQR 3.1 to 4.9). Initial volume received followed the randomization strategy in 155 (97%) patients. By 24-hours, 70 (90%) children in the Tx30 arm had corrected SA compared to 61 (74%) in the Tx20 arm; cause-specific hazard ratio = 1.54 (95% confidence interval 1.09 to 2.18, P = 0.01). From admission to day 28 there was a greater hemoglobin increase from enrollment in Tx30 (global P <0.0001). Serious adverse events included one non-fatal allergic reaction and one death in the Tx30 arm. There were six deaths in the Tx20 arm (P = 0.12); three deaths were adjudicated as possibly related to transfusion, but none secondary to volume overload. CONCLUSION: A higher initial transfusion volume prescribed at hospital admission was safe and resulted in an accelerated hematological recovery in Ugandan children with SA. Future testing in a large, pragmatic clinical trial to establish the effect on short and longer-term survival is warranted. TRIAL REGISTRATION: ClinicalTrials.Gov identifier: NCT01461590 registered 26 October 2011.
Item Type | Article |
---|---|
Keywords | Acute Disease, Africa, Anemia/blood/*therapy, *Blood Transfusion/adverse effects/statistics & numerical data, Child, Preschool, Female, *Hemoglobin A, Hospitalization, Humans, Infant, Male, Acute Disease, Africa, Anemia, blood, therapy, Blood Transfusion, statistics & numerical data, Child, Preschool, Female, Hemoglobin A, Hospitalization, Humans, Infant, Male, Transfusion Reaction |
Faculty and Department | Faculty of Epidemiology and Population Health > Dept of Infectious Disease Epidemiology |
PubMed ID | 24767094 |
ISI | 335993500001 |
Related URLs |
Download
Filename: Phase II trial of standard versus increased transfusion volume in Ugandan children with acute severe anemia_GOLD VoR.pdf
Licence: Creative Commons: Attribution 3.0
Download